Novartis’ Heart Drug Vymada Loses Patent Protection in India

The Indian Patent Office has revoked the patent granted to Novartis for its cardiac drug Vymada under the Patents Act, 1970, citing a lack of novelty.

The drug, marketed globally as Entresto, combines valsartan and sacubitril and generated $7.8 billion in global sales last year. 

Till now, courts had restrained generic versions from companies like Natco, Torrent Pharma, MSN Labs and Eris Lifesciences.

With the revocation, several firms are expected to launch affordable alternatives, potentially reshaping India’s cardiac drug market by driving down prices.